Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Not Applicable

• Conditions: Thyroid Cancer

• Registration Number: NCT02156362
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.

The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05
• Study First Submitted: 2012-05-29
• Study First Submitted QC: 2014-06-04
• Study First Posted: 2014-06-05
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-26
• Last Update Posted: 2021-01-29
• Primary Completion: 2023-05
• Study Completion: 2023-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 643

Inclusion Criteria

• Man or woman ≥ 18 years.
• Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
• TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
• Patient after post operative radioiodine therapy.

Exclusion Criteria

• Patient who can not be followed during the protocol.
• Patient who does not consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Rate of Thyroid cancer evolving to refractory stage	5 years

Trial Locations

Locations (1)

Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel; 🇫🇷 Bron cedex, France